ROCKVILLE, Md., June 13, 2008 - EntreMed, Inc.(Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company overview during the Business Forum at the Biotechnology Industry Organization 2008 Annual International Convention, being held June 17-20, 2008 at the San Diego Convention Center, San Diego, California. Mr. Burns’ presentation is scheduled for Wednesday, June 18, 2008 at 1:00 p.m. (local time).
Mr. Burns’ presentation will not be web cast, however the presentation can be accessed through the Company’s web site at www.entremed.com.
About EntreMed
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company’s web site at www.entremed.com and in various filings with the Securities and Exchange Commission.
CASI Pharmaceuticals © 2024 CASI Pharmaceuticals Inc.
All Rights Reserved.
